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Stathmin is an intracellular phosphoprotein that is overexpressed in a number of human malignancies. Our previous study using
proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell
lines. In the current study, to determine the potential involvement of stathmin in OSCC, we evaluated the state of stathmin protein
and mRNA expression in OSCC-derived cell lines and human primary OSCCs. A significant increase in stathmin expression was
observed in all OSCC-derived cell lines examined compared to human normal oral keratinocytes. In immunohistochemistry, 65% of
the OSCCs were positive for stathmin, and no immunoreaction was observed in corresponding normal tissues. Real-time quantitative
reverse transcriptase–polymerase chain reaction data were consistent with the protein expression status. Moreover, stathmin
expression status was correlated with the TNM stage grading. Furthermore, we found a statistical correlation between the protein
expression status and disease-free survival (P¼0.029). These results suggest that expression of stathmin could contribute to cancer
progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
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Oral squamous-cell carcinoma (OSCC) is the most common cancer
of the head and neck and accounts for over 300000 new cancer
cases worldwide annually (Lippman et al, 2005). With the
currently available clinical assessment and treatment methods,
patients are often diagnosed at late stages and the survival rate has
not improved substantially. This highlights the need for continued
efforts to discover suitable biomarkers for early diagnosis of the
disease and to understand the disease pathogenesis as a first step
toward improving treatment. Elucidation of the genetic changes
leading to the development of OSCCs will probably result in
improved molecular assays for the early diagnosis of, therapy
for, and improved prognosis of this cancer. The availability of
biomarkers of malignancy would also be key for monitoring cancer
recurrence and evaluating the efficacy of novel treatment or
chemopreventive agents.
The proteomic study includes post-translational modifications
such as acetylation, ubiquitination, phosphorylation, or glycosyla-
tion (Larsson et al, 2000; Charlwood et al, 2001). Proteomic
methods can detect the functioning units of expressed genes using
protein fingerprinting (Wilkins et al, 1996; Pandey and Mann,
2000). In addition, many cancer biomarkers are a manifestation
of differences in post-transcriptional splicing, post-translational
modifications, or both. Thus, proteomic tools are used increasingly
in the post-genomic era to discover new cancer biomarkers. Such
information will likely prove to be crucial in cancer prognosis,
diagnosis, prevention, and therapy, with the ultimate goals being
therapeutic target discovery, rational drug design, and identifica-
tion of early-detection surrogate biomarkers (Pandey and Mann,
2000; Rudert, 2000). However, comprehensive proteomic study of
OSCCs to identify the targets of molecules has not yet been
undertaken. In our previous study, using a fluorescent two-
dimensional differential in-gel electrophoresis (2-D-DIGE) system
and matrix-assisted laser desorption/ionisation time-of-flight mass
spectrometry (MALDI–TOF/MS), we compared protein expression
profiles in human normal oral keratinocytes (HNOKs) and OSCC-
derived cell lines and identified several OSCC-associated proteins
(Koike et al, 2005). Among them, the protein stathmin was
associated with tumours. At present, it is unclear whether stathmin
is associated with oral carcinogenesis. The major purpose of this
study was therefore to examine the expression of stathmin protein
and mRNA in OSCC-derived cell lines and human primary OSCCs.
MATERIALS AND METHODS
Tissue specimens and cell lines
Tissue samples from 81 unrelated Japanese patients with primary
SCC of the oral cavity who were treated at the Chiba University
Hospital were obtained at the time of surgical resection between
1998 and 2005. Tumours and patient-matched normal epithelium
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swere obtained at the time of surgery at Chiba University Hospital
after the patients’ informed consent was obtained under a protocol
reviewed and approved by the institutional review board of Chiba
University. The respected tissues were divided into two parts,
one of which was frozen immediately after careful removal of the
surrounding normal tissues and stored at  801C until protein
isolation; the second part was fixed in 10% buffered formaldehyde
solution for pathologic diagnosis and immunohistochemical
staining. Histopathologic diagnosis of each neoplastic tissue was
performed according to the World Health Organization criteria
by the Department of Pathology, Chiba University Hospital.
Clinicopathologic staging was determined by the TNM classifica-
tion of the International Union against Cancer. All patients had
SCC that was confirmed histologically, and tumour samples were
checked to ensure that tumour tissue was present in more than
80% of the specimens.
The follow-up data have been collected until November 2005 or
until the patients’ death, and the occurrence of metastasis and/or
local recurrence was recorded. For the analyses, the patients were
divided into the following two groups depending on the different
kind of outcome. Patients who had no evidence of disease (local
recurrence or metastasis) during follow-up were regarded as a
good prognosis group. In contrast, patients who developed local
recurrence, distant metastasis, and/or death during follow-up,
whichever occurred first were regard as a poor prognosis group.
A follow-up was available for all patients, ranging from 3 to 60
mouths after the primary treatment (median follow-up, 30.3
months). The OSCC-derived cell lines used in this study were HSC-
2, HSC-3, HSC-4, Ca9–22 (Human Science Research Resources
Bank, Osaka, Japan), OK92 (established from carcinoma of
the tongue in our department) (Takahashi et al, 1989), and
Sa3 (provided by Dr Fujita at Wakayama Medical University,
Wakayama, Japan). All OSCC-derived cell lines were grown
in Dulbecco’s modified Eagle medium/F-12 HAM (Sigma-Aldrich
Co., St Louis, MO, USA) supplemented with 10% fetal bovine
serum (Sigma) and 50Uml
 1 penicillin and streptomycin (Sigma).
Healthy oral gingival specimens were collected from 22- to
35-year-old patients at Chiba University Hospital. The institutional
review board of Chiba University approved all relevant protocols.
Five independent HNOK cell lines were cultured and maintained
in defined keratinocyte-SFM (Gibco BRL, Gaithusberg, Germany)
(Koike et al, 2005).
Protein and mRNA extraction
Protein was extracted from the cells when they reached 80–90%
confluence; they were washed twice with phosphate-buffered saline
(PBS), scraped into a tube, and centrifuged briefly. The cell pellets
were incubated for 30min in a lysis buffer (LB) containing 7 M
urea, 2 M thiourea, 4% wv
 1 CHAPS, and 10mM Tris pH 8.0, and
lysed by sonication (3 10s pulses on ice). The sample was
centrifuged at 13 000r.p.m. for 20min. The supernatant containing
the cell proteins then was recovered, and the protein concentration
was measured with a Protein Assay Kit (Bio-Rad Laboratories,
Hercules, CA, USA) and adjusted to 1mgml
 1 with LB. The pH of
the protein sample was adjusted to 8.5 with 30mM Tris-HCl. Total
RNA was extracted using Trizol Reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA), according to the manufac-
turer’s instructions. Each specimen of extracted RNA was stored
separately at  801C until use.
Immunofluorescence
To examine the protein expression of stathmin, we performed
immunofluorescence analysis. Briefly, the cells were washed with
PBS and fixed in 4% paraformaldehyde for 10min at 371C followed
by absolute methanol for 10min at 41C and blocked in PBS
containing 1% skimmed milk for 10min. The samples then were
incubated with affinity-purified rabbit antihuman stathmin poly-
clonal antibody (Abcam Inc., Cambridge, CA, USA) at a dilution
of 1:100 for 2h, rinsed twice with PBS, and incubated with
goat anti-rabbit secondary antibody labelled with Alexa Fluor 350
(Molecular Probes, Leiden, the Netherlands) for 1h. The samples
were observed under a Leica TCS2-MP confocal system (Leica
Laserteknik, Mannheim, Germany) and Coherent Mira tunable
pulsed titanium sapphire laser (Coherent Laser Group, Santa Clara,
CA, USA) (Kasamatsu et al, 2005).
Western blot analysis
Protein extracts were electrophoresed on 11% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels, transferred onto
PVDF membranes (Bio-Rad), and blocked for 1h at room
temperature in 5% skim milk. Immunoblot PVDF membranes
were washed with 0.1% Tween-20 in TBS (TBS-T) five times, and
2mgml
 1 affinity-purified rabbit antihuman stathmin polyclonal
antibody (Abcam) was added directly to the TBS-T solution for 2h
at room temperature. PVDF membranes were washed again and
incubated with a 1:1000 of horseradish peroxidase-conjugated
antirabbit IgG Envisionþ (Dako Japan Inc., Kyoto, Japan) as a
secondary antibody for 20min at room temperature. Finally, the
membranes were incubated with ECLþ-horseradish peroxidase
substrate solution included in the ECLþkit (Amersham Bio-
sciences UK Ltd, UK), and immunoblotting was visualised by
exposing the membrane to Hyperfilm (Amersham) (Endo et al,
2004; Kasamatsu et al, 2005).
Immunohistochemistry
Immunohistochemical staining was performed on 4-mm sections of
paraffin-embedded specimens with the use of rabbit anti-human
stathmin polyclonal antibody (Abcam). Briefly, after deparaffinisa-
tion and hydration, the slides were treated with endogenous
peroxidase in 0.3% H2O2 for 30min, after which the sections were
blocked for 2h at room temperature with 1.5% blocking serum
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBS before
reacting with antistathmin antibody (1:1000 dilution) at room
temperature in a moist chamber for overnight. Upon incubation
with the primary antibody, the specimens were washed three times
in phosphate-buffered saline and treated with Envision reagent
(Dako) followed by colour development in 3,30-diaminobenzidine
tetrahydrochloride (Dako). Finally, the slides were lightly counter-
stained with haematoxylin, dehydrated with ethanol, cleaned with
xylene, and mounted. As a negative control, duplicate sections
were immunostained without exposure to primary antibodies. To
quantitate the state of stathmin protein expression, the mean
percentage of positive tumour cells was determined in at least
five random fields at  400 magnification in each section. The
intensity of the stathmin-immunoreaction was scored as follows:
1þ, weak; 2þ, moderate; and 3þ, intense. The percentage of
positive tumour cells and the staining intensity then were
multiplied to produce a stathmin-immunohistochemical staining
score (Tanaka et al, 2003; Shimada et al, 2005). Cases with a
stathmin score grater than 86.16 (the highest score for normal
tissue) were defined as positive. These judgments were made by
two independent pathologists, neither of whom had knowledge or
information pertaining to the patients’ clinical status. Statistical
significance was evaluated by the Fisher’s exact test or the Mann–
Whitney U-test. Po0.05 was considered significant.
mRNA expression analysis
Among the OSCC cases studied by immunohistochemistry,
expression levels of stathmin mRNA were examined in 20 patients
with OSCC (10 stathmin-negative and 10 stathmin-positive cases)
from whom RNA was available from primary tumours and from
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spaired specimens of normal oral tissue. Control reactions were
prepared in parallel without reverse transcriptase. In addition,
expression levels of stathmin mRNA were examined in OSCC-
derived cell lines (HSC-2, HSC-3, HSC-4, Ca9-22, OK92, and Sa3)
and HNOKs. Real-time quantitative reverse transcriptase–poly-
merase chain reaction (qRT–PCR) was performed with a single
method using a LightCycler FastStart DNA Master SYBR Green 1
Kit (Roche Diagnostics GmbH, Mannheim, Germany), according
to the procedure provided by the manufacturer. The primer
sequences used to analyse stathmin mRNA expression were for-
ward 50-CCCCTTTCCCCTCCAAAGAA-30 and reverse 50-TCGCAA
ACGTTCCAGTTTGG-30. The sequence of specific primers was
checked before use to avoid amplification of genomic DNA
or pseudogenes by Primer3 program (available at http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). The PCR
reactions using LightCycler (Roche) apparatus were carried out
in a final volume of 20ml of a reaction mixture consisting of 2mlo f
FirstStart DNA Master SYBR Green I mix (Roche), 3mM MgCl2,
and 0.2ml of the primers, according to the manufacturer’s
instructions. The reaction mixture was then loaded into glass
capillary tubes and subjected to an initial denaturation at 951C for
10min, followed by 45 rounds of amplification at 951C (10s) for
denaturation, 631C (10s) for annealing, and 721C for extension,
with a temperature slope of 201Cs
 1, performed in the LightCycler.
The transcript amount for the stathmin gene was estimated from
the respective standard curves and normalised to the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (forward 50-CATCT
CTGCCCCCTCTGCTGA-30 and reverse 50-GGATGACCTTGCCCA
CAGCCT-30) transcript amount determined in corresponding
samples. The statistical significance of the gene expression levels
between stathmin-positive and stathmin-negative cases was
calculated with the Mann–Whitney U-test. Po0.05 was considered
significant. Data are expressed as the means (7s.d.) of two
independent experiments with triplicate samples.
Statistical analysis
The overall survival time was defined as the interval between the
date of treatment and the date of death or until the last objective
follow-up information was obtained. Disease-free survival time
was regarded as the time interval between tumour treatment and
detection of the first locoregional recurrence and/or distant
metastasis or the date of last follow-up, whichever occurred first.
Disease-free survival or overall survival according to stathmin
overexpression was constructed using Kaplan–Meier method. The
comparison among curves was performed by the log-rank test with
95% of significance.
RESULTS
Analyses of protein expression of stathmin in OSCC-
derived cell lines
We previously showed the upregulation of stathmin in OSCC-
derived cell lines (HSC-3 and HSC-2) (Koike et al, 2005). In the
current study, we further assessed the level of stathmin protein
expression in OSCC-derived cell lines (HSC-3 and HSC-2) and
HNOKs by immnofluorescence analysis. Figure 1A shows typical
results of immnofluorescence. Strong immunoreactivity of stathmin
protein was detected in the cytoplasm of OSCC-derived cell
lines compared with the HNOKs. We also evaluated the state of
stathmin protein expression in four additional OSCC-derived cell
lines (HSC-4, ca9–22, OK92, and Sa3) by Western blot analysis.
Figure 1B shows representative results. The size of the band was
detected as 17kDa, as reported by Feuerstein and Cooper (1983),
and a significant increase in stathmin expression was observed in
HNOKs
HSC-3
HSC-2
HSC-4
Ca9-22
Sa3
O
K
9
2
Stathmin
B
A
HNOK HSC-2 HSC-3
Figure 1 Representative results of expression of stathmin protein in
OSCC-derived cell lines. (A) Immunocytochemical analysis shows strong
immunoreactivity of stathmin in OSCC-derived cell lines (HSC-2 and HSC-
3) compared with the HNOKs. (B) Western blot analysis of stathmin
protein in OSCC-derived cell lines and HNOKs. HNOKs extracts do not
significantly express stathmin protein. OSCC-derived-cell lines extracts
exhibiting stathmin protein expression.
Table 1 Correlation between the expression of Stathmin and clinical
classification in OSCCs
Immunostaining
results (no. of
patients (%))
Clinical classification Total
Stathmin
( )
Stathmin
(+) P-value
a
Age at surgery (years)
o60 22 8 (36) 14 (64)
60 p, o70 26 6 (23) 20 (77) 0.654
70p 33 14 (42) 19 (58)
Gender
Male 48 16 (33) 32 (67) 0.961
Female 33 12 (36) 21 (64)
T-primary tumour
T1 10 7 (70) 3 (30)
T2 39 15 (38) 24 (62) 0.149
T3 13 2 (15) 11 (85)
T4 19 4 (21) 15 (79)
N-regional lymph node
N( ) 41 18 (44) 23 (56) 0.202
N(+) 40 10 (25) 30 (75)
Stage
I 8 6 (75) 2 (25)
II 21 11 (52) 10 (48) 0.035
III 13 4 (31) 9 (69)
IV 39 7 (18) 32 (72)
Histopathologic type
Well differentiated 51 17 (33) 34 (67)
Moderately differentiated 22 8 (36) 14 (64) 0.999
Poorly differentiated 8 3 (38) 5 (62)
Tumour site
Gingiva 27 6 (22) 21 (78)
Tongue 30 15 (50) 15 (50) 0.997
Buccal mocosa 7 2 (29) 5 (71)
Oral floor 10 3 (30) 7 (70)
Oropharynx 7 1 (14) 6 (86)
aA provability of Po0.05 was defined as significant.
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sall OSCC-derived cell lines compared with the HNOKs. Immno-
fluorescence and Western blotting experiments confirmed the
results from 2-D gel analysis and protein identification by mass
spectrometry.
Immunohistochemistry
A total of 81 patients with OSCC were identified for whom
there was adequate histologic material available for immunohisto-
chemical analysis. The correlation between the clinicopathologic
characteristics of the patients with OSCC and the status of
stathmin expression is summarised in Table 1. Normal oral
mucosa specimens had no or significant downregulation of
stathmin expression and were considered stathmin-negative
(Fisher’s exact test). Among the tumours examined, 53 of 81 cases
(65%) had a stathmin immunoreaction in the cytoplasm of the
tumour cells (Table 1). Moreover, expression of these proteins was
correlated with the TNM stage grading of OSCCs (P¼0.035;
Table 1). Representative results for stathmin protein expression
in normal oral tissue and primary OSCCs are shown in Figure 2.
The stathmin-immunohistochemistry scores for normal tissues
and OSCCs ranged from 8.77 to 86.16 (mean, 32.59) and 21.83
to 231.0 (mean, 101.6), respectively. The stathmin expression levels
in primary OSCCs were significantly higher than those in normal
oral tissues (Mann–Whitney U-test, Po0.0001; Figure 3). Further-
more, the stathmin-immunohistochemistry scores for early stages
(I and II) and advanced stages (III and IV) ranged from 21.83
to 199.4 (mean, 80.56) and 32.6 to 230.9 (mean, 113.1),
respectively. The stathmin expression levels were significantly
higher in the OSCC group with advanced stage disease compared
with the group with early stage disease (Mann–Whitney U-test,
Po0.001; Figure 4).
A
B
C
Figure 2 Immunohistochemical staining of stathmin in normal and
primary OSCCs. (A) Normal oral tissue shows no stathmin protein
expression. Original magnification,  200. (B) Stathmin-positive case of
OSCC. Strong positive immunoreaction for stathmin is detected in the
cytoplasm. Original magnification,  200. (C) The border between normal
epithelium (right side) and the dysplastic lesion (left side) is seen. While no
stathmin expression is detected in normal epithelial cellular cytoplasm,
strong stathmin protein expression is evident in the lesion. Original
magnification,  100.
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Figure 3 State of stathmin protein expression in normal tissues (n¼81)
and primary OSCCs (n¼81). The stathmin-immunohistochemistry scores
are calculated as follows: stathmin-immunohistochemistry score¼(% of
positive tumour cells) the staining intensity. Stathmin protein expression
in OSCCs is significantly higher than in normal oral tissues (Po0.0001,
Mann–Whitney U-test). The results represent the mean7s.d. IHC,
immunohistochemistry.
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Figure 4 State of stathmin protein expression in patients with early-
stage (I and II) OSCC (n¼29) and patients with advanced stages (III and
IV) OSCC (n¼52). The stathmin-immunohistochemistry scores are
calculated as follows: stathmin-immunohistochemistry score¼(% of
positive tumour cells) the staining intensity. Stathmin protein expression
in advanced stages is significantly higher than in the early stages (Po0.001,
Mann–Whitney U-test). The results represent the mean. IHC, immuno-
histochemistry.
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qRT–PCR analysis data were matched to protein expression levels
studied by immunohistochemistry scores. The stathmin mRNA
expression levels were significantly increased in primary tumours
of randomly selected stathmin-positive cases (n¼10) compared
with randomly selected stathmin-negative cases (n¼10, Mann–
Whitney U-test, Po0.001; Figure 5A). Relative mRNA expression
levels in negative and positive cases ranged from 11 to 35.6 (mean,
22.5) and 48 to 500.3 (mean, 163.7), respectively. As shown in
Figure 5B, a significant increase in the expression of stathmin
mRNA occurred in all OSCC-derived cell lines examined compared
with the HNOKs. The stathmin mRNA expression levels for the
HNOKs and OSCC-derived cell lines ranged from 15.1 to 23.1
(mean, 19.4) and 56 to 200.3 (mean, 95.8), respectively. Therefore,
stathmin mRNA expression levels were consistent with the protein
expression status.
Prognostic significance of stathmin expression in OSCC
The disease-free survival curves in relation to stathmin over-
expression are shown in Figure 6A. Stathmin overexpression was
found to be a significant for disease-free survival by the log-rank
survival analysis (P¼0.029). The overall survival curves in relation
to stathmin overexpression are shown in Figure 6B. Although
stathmin overexpression is poorer than that of the stathmin
negative expression, no significant difference was found
(P¼0.161). Because the length of follow-up ranged from 3 to 60
months, 5-year survival could not be yet available.
DISCUSSION
Because the functional molecules in cells are protein, proteome
analysis based on 2-D gel electrophoresis is believed to have
several advantages over cDNA/oligonucleotide microarray systems
for clinical use. Proteomic studies of clinical tumour samples have
led to the identification of cancer-specific protein markers, which
provide a basis for developing new methods for early diagnosis
and early detection and clues to understanding the molecular
characterisation of cancer progression (Emmert-Buck et al, 2000;
Hanash, 2000; Liotta and Petricoin, 2000; Prasannan et al, 2000).
Previously, we reported that a significant increase in stathmin
protein expression was observed in OSCC-derived cell lines, using
a 2-D-DIGE system and MALDI-TOF/MS (Koike et al, 2005).
Stathmin was first identified as a 17-kDa cytosolic protein that
is rapidly phosphorylated when HL60 leukemic cells undergo
terminal differentiation and cease to proliferate (Feuerstein and
Cooper, 1983). In addition, stathmin is a conserved cytosolic
protein that has been studied in various cellular systems such as
oncoprotein 18, prosolin, p19, 19K, p18, and op18 (Belmont and
Mitchison, 1996; Laird and Shalloway, 1997). Recent studies have
reported that this gene plays a critical role in mitosis and possibly
other cellular processes (Rubin and Atweh, 2004). Therefore,
stathmin has attracted the attention of many investigators because
of its high level of expression in many types of cancer, including
leukemia and lymphoma (Hanash et al, 1988; Luo et al, 1991;
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Figure 5 Stathmin mRNA expression status in primary OSCCs and
OSCC-derived cell lines. (A) Comparison of stathmin mRNA expression
levels between stathmin-positive and stathmin-negative cases classified by
immunohistochemistry analysis. There is a significant difference in the
stathmin mRNA expression levels between negative and positive cases
(Po0.001, Mann–Whitney U-test). (B) Quantification of mRNA levels in
OSCC-derived cell lines by qRT–PCR analysis. Significant upregulation of
the stathmin gene is seen in all OSCC-derived cell lines compared to
stathmin mRNA expression in HNOKs. Data are expressed as means7s.d.
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Figure 6 Kaplan–Meier curves for disease-free survival (A) or overall
survival (B) according to stathmin overexpression in patients with OSCC
(log-rank test, A, P¼0.029; B, P¼0.161). When stathmin overexpression
was observed, survival rate was not significant (B), but disease rate
increased significantly (A).
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sGhosh et al, 1993; Roos et al, 1993), prostate carcinoma (Friedrich
et al, 1995), ovarian carcinoma (Price et al, 2000), Wilms’ tumour
(Takahashi et al, 2002), breast carcinoma (Bieche et al, 1998), and
adenoid cystic carcinoma of the salivary glands (Nakashima et al,
2005). Recent studies have reported that stathmin is highly
expressed in more advanced stages of the disease in Wilms’ tumour
(Takahashi et al, 2002). In addition, high protein expression of
stathmin correlated with a poor prognosis in breast cancer
(Brattsand, 2000). However, the status of stathmin in OSCC remains
unclear. Thus, we selected stathmin for further investigation.
To clarify the relative status of stathmin in OSCC, we
investigated the protein/mRNA expression in a series of OSCC-
derived cell lines and human primary OSCCs using immunofluor-
escence, Western blot analysis, qRT–PCR, and immunohisto-
chemistry. Significant increases in stathmin protein and mRNA
expression levels were observed in the OSCC-derived cell lines
examined compared with the HNOKs. We also detected a
comparatively strong tumour cell-localised cytoplasmic stathmin-
immunoreaction in primary OSCCs. By evaluating the stathmin
immunohistochemistry scores using the Mann–Whitney U-test,
significant stathmin upregulation was evident in the primary
OSCCs (Po0.0001, OSCC vs corresponding normal tissues)
compared with normal tissues. qRT–PCR analysis data were
matched to protein expression levels studied by Western blot
analysis and immunohistochemistry. The stathmin protein ex-
pression levels in primary OSCCs were significantly associated
with TNM stage grading (P¼0.035). Moreover, the state of the
protein stathmin expression differed significantly between the
early stages (I and II) and the advanced stages (III and IV)
(Mann–Whitney U-test, Po0.001). Our results suggest a signifi-
cant association between stathmin and the clinical stages of
tumours, with upregulation of stathmin in the advanced stages (III
and IV) of OSCC, which may result in tumour aggressiveness and
the progression of OSCC. Moreover, this study has shown that the
stathmin overexpression is closely related to the disease-free
survival (P¼0.029), suggesting that stathmin could be a novel
prognostic/therapeutic marker.
Recent studies have shown that inhibition of stathmin expres-
sion in malignant cells interferes with their orderly progression
through the cell cycle and abrogates their transformed phenotype
(Mistry and Atweh, 2002). Thus, stathmin provides an attractive
molecular target for disrupting the mitotic apparatus and arresting
the growth of malignant cells. In addition, several studies have
shown that stathmin is a potential therapeutic target because a
stathmin-transfected lung cancer cell line has increased sensitivity
to Vinca alkaloids (Nishio et al, 2001), and antisense inhibition of
stathmin expression showed a synergistic apoptotic effect in
combination with paclitaxel treatment (Iancu et al, 2000). Further
studies with a larger population will improve our ability to treat
this cancer.
Based on our data, we have concluded that stathmin is not only
frequently overexpressed in OSCC, but also may play an important
role in the progression and patient prognosis of this disease.
In addition, the differential expression status of stathmin between
the early and advanced stages of OSCC may provide insights into
the process of tumorigenicity and for planning new treatment
strategies.
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